Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of combined anti-VEGF-anti-PD1 bispecific antibody in preparation of anti-cancer drug

A bispecific antibody and anti-cancer drug technology, applied in the direction of antibodies, anti-tumor drugs, drug combinations, etc., can solve problems such as low production efficiency, poor pharmacokinetic performance, and difficulties in the development of bispecific antibodies, and achieve improved Coverage, increase the effect of suppression effect

Pending Publication Date: 2020-04-07
ANHUI RUBIOX VISION BIOTECH
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are more than 40 types of bifunctional antibody forms that have been developed, but due to problems such as low production efficiency and poor pharmacokinetic performance, the development of bispecific antibodies has always been difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combined anti-VEGF-anti-PD1 bispecific antibody in preparation of anti-cancer drug
  • Application of combined anti-VEGF-anti-PD1 bispecific antibody in preparation of anti-cancer drug
  • Application of combined anti-VEGF-anti-PD1 bispecific antibody in preparation of anti-cancer drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The anticancer drug includes ouabain and anti-VEGF-anti-PD1 bispecific antibody, the content of the anti-VEGF-anti-PD1 bispecific antibody in 0.1ml of the anticancer drug is 0.01mg, and the anticancer drug 0.1ml The content of ouabain in the medium is 0.02 mg; the CDR-H1 of the heavy chain variable region of the anti-VEGF-anti-PD1 bispecific antibody is the amino acid sequence shown in SEQ ID NO: 1, and the CDR-H2 is the amino acid sequence shown in SEQ ID NO : the amino acid sequence shown in 2, and CDR-H3 is the amino acid sequence shown in SEQ ID NO: 3; and the CDR-L of the light chain variable region of the anti-VEGF-anti-PD1 bispecific antibody is SEQ ID NO: The amino acid sequence shown in 4.

[0019] The heavy chain amino acid sequence of the anti-VEGF-anti-PD1 bispecific antibody is shown in SEQ ID NO:5, and the light chain amino acid sequence of the anti-VEGF-anti-PD1 bispecific antibody is shown in SEQ ID NO:6.

[0020] The preparation method of the anti-VEGF...

Embodiment 2

[0023] On the basis of Example 1, the content of ouabain in 0.1 ml of the anticancer drug is 0.04 mg, and the other ingredients and ratios are the same as in Example 1.

Embodiment 3

[0025] On the basis of Example 1, the content of ouabain in 0.1 ml of the anticancer drug is 0.06 mg, and the other ingredients and ratios are the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of anti-cancer drug, and particularly discloses an anti-cancer drug combining jabaine with an anti-VEGF-anti-PD1 bispecific antibody. The anti-cancer drugis prepared from jabaine and the anti-VEGF-anti-PD1 bispecific antibody. The content of the anti-VEGF-anti-PD1 bispecific antibody in 0.1ml of the anti-cancer drug is 0.01mg, and the content of jabaine in 0.1ml of the anti-cancer drug is 0.02mg to 0.06mg. CDR-H1 of a heavy chain variable region of the anti-VEGF-anti-PD1 bispecific antibody is an amino acid sequence shown as SEQ ID NO:1. CDR-H2 isan amino acid sequence shown as SEQ ID NO:2. CDR-H3 is an amino acid sequence shown as SEQ ID NO:3. CDR-L of the light chain variable region of the anti-VEGF-anti-PD1 bispecific antibody is an amino acid sequence shown as SEQ ID NO:4. According to the invention, defects in the prior art are overcome; and the anti-cancer property of the anti-cancer drug is improved by utilizing the combined actionof jabaine and the bispecific antibody.

Description

technical field [0001] The invention relates to the technical field of anticancer drugs, in particular to an anticancer drug combined with ouabain and anti-VEGF-anti-PD1 bispecific antibody. Background technique [0002] Vascular endothelial growth factor (vascular endothelial growth factor, VEGF), also known as vascular permeability factor (vascular permeability factor, VPF), is a highly specific factor that promotes the growth of vascular endothelial cells. endothelial cell migration, proliferation and angiogenesis. Vascular endothelial growth factors are a family that includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor (PGF). Usually VEGF is VEGF-A. VEGF-A can promote the formation of new blood vessels and increase the permeability of blood vessels, VEGF-B plays a role in non-neovascular tumors, VEGF-C and VEGF-D play a role in the formation of new blood vessels and new lymphatic vessels in cancer tissues VEGF-E is also a potential neovasculari...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K39/395A61P35/00
CPCA61K31/7048A61K39/39558A61P35/00C07K16/22C07K16/2818C07K2317/31A61K2300/00
Inventor 汪国兴袁红武婷樊丽
Owner ANHUI RUBIOX VISION BIOTECH